Atea Pharmaceuticals Inc. recently presented preclinical data on two of its compounds, AT-2490 and AT-587, which have shown promising antiviral potential for treating hepatitis E virus infection.

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. This fact sheet provides information about transmission, symptoms, diagnosis, treatment, prevention and WHO's work to support prevention and treatment.

Wastewater surveillance in Ahmedabad, Gandhinagar, Vadodara and Rajkot detected 305 virus species, showing early warning potential for Covid, hepatitis and GI viruses.

Food safety fact sheet provides key facts and information on major foodborne illnesses, causes, evolving world and food safety and WHO response.

Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E VirusBOSTON, May 27, 2026 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral […]

Most HCV patients juggle drugs. Phase 1 data show Atea’s BEM/RZR works with PPIs and statins, while AT-587 shows HEV activity in lab and animal tests.

Hepatitis E vaccine safety data show no detected rise in fetal loss during pregnancy. Read more.

A Phase 3 trial testing a combination therapy in adults with chronic hepatitis C remains on track, with topline results expected soon.

Researchers at the Ruhr University Bochum have developed a novel antiviral concept: Using the CRISPR/Cas13 system, they were able to specifically suppress the replication of the hepatitis E virus in human …

Hong Kong’s health authorities on Saturday confirmed the city’s first local case of human infection of rat Hepatitis E virus this year, urging the public to take effective rodent prevention and control measures.

Janitors were seen deep-cleaning public areas at Laguna Verde, where patient reportedly lived, on Sunday.

Hong Kong health authorities said today (May 16) they are investigating the city's first local human case of rat hepatitis E virus (HEV) infection this year, involving a 42-year-old man living and working in Hung Hom.

Hong Kong health authorities are investigating a rare case of human infection by the rat hepatitis E virus involving a 42-year-old man, marking the first such diagnosis in the city this year and prompting a fresh warning for residents to maintain strict hygiene standards.

Patient, 42, says he did not encounter rodents at home or at work before positive test on May 5, while three household contacts remain asymptomatic.

CHP investigates local case of human infection of rat Hepatitis E virusThe Centre for Health Protect

CHP investigates local case of human infection of rat Hepatitis E virusThe Centre for Health Protect

WHO fact sheet on hepatitis A provides key facts and information on transmission, who is at risk, treatment, prevention, immunization and WHO's work in this area.

Atea Pharmaceuticals announces three abstracts accepted for presentation at EASL 2026, highlighting advancements in hepatitis treatments.Quiver AI SummaryAtea Pharmaceuticals, Inc. announced that three abstracts have been accepted for presentation at the EASL Congress 2026 in Barcelona from May 27-30, focusing on new antiviral therapies for hepatitis C and hepatitis E. The presentations will showcase two […]

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

A CRISPR-based antiviral strategy suppressed hepatitis E virus replication in cell cultures. Researchers used targeted RNA-cutting molecules designed to cover multiple viral variants.